Stifel analyst Jonathan Block, who hosted meetings with senior management of Envista (NVST) as part of the firm’s West Coast bus tour, reports that management described the current dental market as “stable plus,” which is an improvement from the company’s prior “stable” and at times “slow, but stable” messaging throughout 2025. The firm, which thought management sounded “upbeat” regarding the overall dental market, keeps a Buy rating on Envista shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST:
- Envista initiated with an Overweight at Barclays
- Envista price target raised to $19 from $18 at Mizuho
- Envista Holdings’ Earnings Call Highlights Strong Growth
- Envista price target raised to $27 from $25 at Baird
- Envista Holdings: Strong Q3 Performance and Upward Guidance, Yet Valuation Concerns Justify Hold Rating